Reuters logo
BRIEF-Bellerophon announces FDA agreement on phase 2B study design for Inopulse
August 3, 2017 / 1:15 PM / 4 months ago

BRIEF-Bellerophon announces FDA agreement on phase 2B study design for Inopulse

Aug 3 (Reuters) - Bellerophon Therapeutics Inc

* Bellerophon announces FDA agreement on phase 2B study design for Inopulse in pulmonary hypertension associated with interstitial lung disease (PH-ILD)

* Bellerophon Therapeutics -‍met with FDA in June to present positive results from its recently completed phase 2A study in idiopathic pulmonary fibrosis​

* Bellerophon Therapeutics Inc - ‍agency accepted co’s proposed phase 2B study design as well as an ind application to assess effect of inopulse​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below